Form 4: Senti Biosciences Director Receives New Stock Option Grant

Senti Biosciences, Inc. Director Bryan Daniel Baum was granted 43,900 stock options with an exercise price of $1.95, vesting over three years starting July 18, 2025.

Summary

• Bryan Daniel Baum, a Director of Senti Biosciences, Inc. (SNTI), was granted 43,900 stock options.
• The options have an exercise price of $1.95 per share.
• The transaction date for this grant was July 18, 2025.
• The options will vest in 36 substantially equal monthly installments over three years, commencing from July 18, 2025.
• Vesting is contingent upon Mr. Baum's continued service to the company through the applicable vesting dates.
• The options have an expiration date of July 18, 2035.
• Following this transaction, Mr. Baum beneficially owns 43,900 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with shareholders and is a standard form of compensation, indicating stability in governance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining qualified directors and executives in the biotechnology sector.

Future Outlook

The vesting schedule of the stock options over three years from July 18, 2025, indicates an expectation of continued service from Director Bryan Daniel Baum.

Industry Context

The grant of stock options is a common form of equity compensation for directors and executives in the biotechnology industry, used to align management incentives with shareholder value creation and to retain key talent.

Comparison to Industry Standards

• The structure of this equity grant, involving stock options with a multi-year vesting schedule, is consistent with typical compensation practices observed across the biotechnology and pharmaceutical sectors for non-employee directors.
• Comparable companies in the early-stage biotech space often utilize similar equity incentives to attract and retain board members, given the long development cycles and capital-intensive nature of the industry.

Related Party Transactions

• The grant of stock options to Bryan Daniel Baum, a Director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from increased alignment of director's interests with long-term company performance.
• Director (Bryan Daniel Baum): Receives equity compensation, incentivizing continued service and contribution to the company's success.

Next Steps

• Bryan Daniel Baum's continued service to Senti Biosciences, Inc. is required for the stock options to vest according to the 36-month schedule.

Key Dates

Keywords

Senti Biosciences, SNTI, Stock Option, Equity Grant, Director Compensation, SEC Form 4, Insider Transaction, Biotechnology